Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states

Annals of Oncology

Volumn 24, Issue 11, 2013, Pages 2897-2902

  Ades, F ^a   Senterre, C ^b   de Azambuja, E ^a   Sullivan, R ^c   Popescu, R ^d   Parent, F ^b   Piccart, M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d KLINIK HIRSLANDEN   (Switzerland)

Author keywords

Breast cancer; Cancer indicators; European union; Health and wealth indicators; Health expenditure; Health policy

Indexed keywords

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SCREENING; EUROPEAN UNION; GROSS NATIONAL PRODUCT; HEALTH CARE COST; HEALTH CARE DISPARITY; HUMAN; PRIORITY JOURNAL; RESOURCE ALLOCATION;

BREAST CANCER; CANCER INDICATORS; EUROPEAN UNION; HEALTH AND WEALTH INDICATORS; HEALTH EXPENDITURE; HEALTH POLICY;

EUROPEAN UNION; HEALTH EXPENDITURES; HUMANS; INCIDENCE; NEOPLASMS; SOCIOECONOMIC FACTORS;

EID: 84886725449     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt352     Document Type: Article

References (35)

1. European Union. Official Journal of the European Union - Treaty of Lisbon. Brussels: European Union 2007.
2. How the European Union works. [on-line] Available from: http://ec.europa.eu/publications/booklets/eu_glance/68/index_en.htm (9 August 2012, date last accessed).
3. Going for growth the economy of the EU. [on-line] Available from: http://ec.europa. eu/publications/booklets/move/40/index_en.htm (9 August 2012, date last accessed).
4. Freedom, security and justice for all Justice and home affairs in the European Union. [on-line] Available from: http://ec.europa.eu/publications/booklets/move/42/index_en.htm (9 August 2012, date last accessed).
5. The Schengen area and cooperation. [on-line]. Available from: http://europa.eu/legislation_summaries/justice_freedom_security/free_movement_of_persons_ asylum_immigration/l33020_en.htm (9 August 2012, date last accessed).
6. Jakubowski E, Busse R. Health Care Systems in the EU-a comparative study. [on-line]. EUROPEAN PARLIAMENT L-2929 LUXEMBOURG; 1998. Available from: http://www.europarl.europa.eu/workingpapers/saco/pdf/101_en.pdf (9 September 2013, date last accessed).
7. Charter of Fundamental Rights. [on-line] Available from: http://europa.eu/legislation_summaries/justice_freedom_security/combating_discrimination/ l33501_en.htm (9 August 2012, date last accessed).
8. Directorate General for Health & Consumers - European Commission. [on-line] Available from: http://ec.europa.eu/dgs/health_consumer/index_en.htm (10 August 2012, date last accessed).
9. European Health Insurance Card-Employment, Social Affairs & Inclusion- European Commission. [on-line] Available from: http://ec.europa.eu/social/main. jsp?catId=559 (10 August 2012, date last accessed).
10. wcr_2008. pdf [on-line]. Available from: http://www.iarc.fr/en/publications/pdfsonline/ wcr/2008/wcr_2008.pdf (18 December 2012, date last accessed).
11. Mackenbach JP, Karanikolos M, McKee M. The unequal health of Europeans: successes and failures of policies. Lancet 2013; 381(9872): 1125-1134.
12. UNITED NATIONS DGACM. [on-line] Available from: http://www.un.org/depts/ DGACM/RegionalGroups.shtml (27 December 2012, date last accessed).
13. GLOBOCAN. [on-line] 2008; Available from: http://globocan.iarc.fr/ (18 December 2012, date last accessed).
14. WHO. World Health Statistics. [on-line] 2012; Available from: http://www.who.int/ gho/publications/world_health_statistics/2012/en/ (18 December 2012, date last accessed).
15. IMF Annual Report 2009 - Table of Contents, Highlights [on-line] Available from: http://www.imf.org/external/pubs/ft/ar/2009/eng/index.htm (18 December 2012, date last accessed).
16. WDRs - Full Text: WDR 2011 [on-line] Available from: http://web.worldbank.org/WBSITE/EXTERNAL/EXTDEC/EXTRESEARCH/EXTWDRS/0,contentMDK:23256432~pagePK:478093~piPK:477627~theSitePK:477624,00.html (18 December 2012, date last accessed).
17. Indicators Data [on-line]. Available from: http://data.worldbank.org/indicator (22 March 2013, date last accessed).
18. Blumberg BS. Hepatitis B virus and the control of hepatocellular carcinoma. IARC Sci Publ 1984; (63): 243-261.
19. Cogliano V, Straif K, Baan R et al. Smokeless tobacco and tobacco-related nitrosamines. Lancet Oncol 2004; 5(12): 708.
20. Baan R, Straif K, Grosse Y et al. Carcinogenicity of alcoholic beverages. Lancet Oncol 2007; 8(4): 292-293.
21. Chen Y, Wang X, Wang J et al. Excess body weight and the risk of primary liver cancer: an updated meta-analysis of prospective studies. Eur J Cancer 2012; 48 (14): 2137-2145.
22. Fletcher SW, Black W, Harris R et al. Report of the International Workshop on Screening for Breast Cancer. J Natl Cancer Inst 1993; 85(20): 1644-1656.
23. Siegel R, Ward E, Brawley O et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-236.
24. 16-year Mortality from breast cancer in the UK Trial of Early Detection of Breast Cancer. Lancet 1999; 353(9168): 1909-1914.
25. Nyström L, Andersson I, Bjurstam N et al. Long-term effects of mammography screening: updated overview of the swedish randomised trials. Lancet 2002; 359 (9310): 909-919.
26. Van Dijck JA, Holland R, Verbeek AL et al. Efficacy of mammographic screening of the elderly: a case-referent study in the Nijmegen program in The Netherlands. J Natl Cancer Inst 1994; 86(12): 934-938.
27. Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011; 378(9793): 771-784.
28. Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28(3): 509-518.
29. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365(14): 1273-1283.
30. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353(16): 1659-1672.
31. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011; 12(3): 236-244.
32. Perez EA, Romond EH, Suman VJ et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B- J Clin Oncol 2011; 29(25): 3366-3373.
33. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355(26): 2733-2743.
34. Baselga J, Cortés J, Kim S-B et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366(2): 109-119.
35. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367(19): 1783-1791.